—
C+
C+ The full Closelook — membership. Open the C+ overview

Apogee Therapeutics, Inc. Common Stock (APGE) — chart, structure and Closelook read

Home› Indices›
Pick a ticker to load its detail page.

Company snapshot — Apogee Therapeutics, Inc. Common Stock

APGE in five paragraphs: what it makes and sells, where it sits in the Closelook stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
Apogee Therapeutics develops biologic therapies for immunological and inflammatory diseases, building a pipeline of monoclonal antibodies for conditions such as atopic dermatitis, asthma and chronic obstructive pulmonary disease. Its lead candidates target pathways including OX40L, IL-4Ra and TSLP, and are designed to let patients inject less often. Founded in 2022 and based in San Francisco, the company now operates as a subsidiary of AbbVie.
Where it sits in the stack
Apogee holds no seat in our index; it sits in the Healthcare sector of the Closelook universe, among US drug developers the diary follows for pipeline progress and balance-sheet risk rather than for any place in the AI build-out.
Who it is priced against
Closelook's peer group compares it with other scored Healthcare names based in the US, including argenx, Regeneron and Vertex, grouped for sharing sector and country rather than mechanism; the market also names Amgen as a comparable immunology developer.
Why Closelook tracks it
Apogee carries a Closelook score built from two of the module set so far, with momentum reading stronger than quality; it holds no seat in our index and the diary has not yet quoted it in an edition.
What the diary watches
The diary watches how Apogee's pipeline programmes are reported now that it operates as an AbbVie subsidiary, since that change in ownership affects how trial results and disclosures reach the market.

Apogee Therapeutics, Inc. Common Stock (APGE) trades on US exchanges, classified under Healthcare.

The Closelook company score reads 39/100 composite (momentum 96, quality 3, valuation —) across 6 modules — the full breakdown, chart structure and analog history load live above.

Written from the company’s public profile and Closelook’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

Signals for this name

Every Closelook reading that exists for APGE, from the same nightly bakes the boards use. Research diary readings, not advice.

The Street on this name 1 analyst action on the wire · latest: price target by Truist, 2026-08-13

The Street on this name

Analyst actions and the latest print for APGE from the Closelook wires — third-party opinions on the record, not our readings.

  • Price target Truist — target 135 from 81 Target raised to $135 from $81 (+0.3% to spot) 2026-08-13

1 action on the analyst wire since 2026-08-13: 1 target change. Analyst wire → · Earnings wire →

Who it is priced against Biotechnology · US · 8 names with week and year-to-date

Peer group

Biotechnology · US

Names in the same industry from the Closelook universe; scored names rank on their Closelook score, the rest on trend state.

Compared against APGE on the nightly bakes; the Peers tab ranks the cohort on the Closelook scores where it exists.

Dividends and capital return no distribution in twelve months

Dividends and capital return

What APGE pays out and buys back — distributions read from the price series, money terms from the filings.

  • Distributions No cash distribution recorded in the price series over the last three years
  • Share count +10.0% in FY2025 46 m USD of stock-based compensation in the year

Per-share amounts are derived from the adjusted price series in the listing currency, so dates sit within days of the ex-date; filing figures come from the fundamentals feed for the last reported fiscal year. An investment diary, not a recommendation.

Weather around the name 4 macro readings: Money Temperature, Factor regime, Sector × region …

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 66/100 · S&P 500 fund at 64, bullish alignedEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-09-22
  • Factor regime Momentum leading — risk appetite buildingMomentum against low volatility (SPMO / SPLV): above its 50-day trend, 99th percentile of the window, +10.8% over 20 sessions. Factor regime → 2026-09-22
  • Sector × region Health care in US: +1.7% week · −2.3% month · +12.1% quarter · +12.6% yearThe Sector Engine cell this name lives in, from XLV.US; the 11 × 4 matrix shows where its sector is being bought and where it is being sold. Sector Engine → 2026-09-22
  • Sovereign pressure Index -0.03 · down 0.40 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-09-22

FAQ · from the current data · as of 2026-09-23

Quick answers

What is Apogee Therapeutics, Inc. Common Stock (APGE)?

Apogee Therapeutics, Inc. Common Stock trades as APGE on the US exchange (US) and is classified under Healthcare in the Closelook research universe, as of the registry build of 2026-09-23.

Is APGE in a Closelook index?

Not currently — Apogee Therapeutics, Inc. Common Stock is tracked in the Closelook research universe but is not a constituent of a Closelook functional index as of 2026-09-23.

What is Apogee Therapeutics, Inc. Common Stock's Closelook composite score?

39 out of 100, with momentum 96, quality 3 and valuation n/a sub-scores, as of 2026-09-23. Scores are Closelook's own research readings, not ratings or investment advice.

Where does APGE trade against its moving averages?

Uptrend stack intact: Trades +0.7% vs the 50-day and +46.3% vs the 200-day average, 0% below the 52-week high and +281.7% off the 52-week low. Computed from daily closes. As of 2026-09-03 — a technical state from the nightly Closelook bake, not advice. The Technical tab carries the full row.

What does Apogee Therapeutics, Inc. Common Stock do?

Apogee Therapeutics develops biologic therapies for immunological and inflammatory diseases, building a pipeline of monoclonal antibodies for conditions such as atopic dermatitis, asthma and chronic obstructive pulmonary disease. Its lead candidates target pathways including OX40L, IL-4Ra and TSLP, and are designed to let patients inject less often. Founded in 2022 and based in San Francisco, the company now operates as a subsidiary of AbbVie. Closelook's peer group compares it with other scored Healthcare names based in the US, including argenx, Regeneron and Vertex, grouped for sharing sector and country rather than mechanism; the market also names Amgen as a comparable immunology developer.

Where does Apogee Therapeutics, Inc. Common Stock sit in the AI build-out?

Apogee holds no seat in our index; it sits in the Healthcare sector of the Closelook universe, among US drug developers the diary follows for pipeline progress and balance-sheet risk rather than for any place in the AI build-out. Apogee carries a Closelook score built from two of the module set so far, with momentum reading stronger than quality; it holds no seat in our index and the diary has not yet quoted it in an edition.

Does Apogee Therapeutics, Inc. Common Stock pay a dividend?

No cash distribution shows in Apogee Therapeutics, Inc. Common Stock’s price series over the last three years. The share count rose 10.0% over the fiscal year. The "Dividends and capital return" block on this page carries the lines.

What has Wall Street done on Apogee Therapeutics, Inc. Common Stock recently?

The most recent analyst action on Apogee Therapeutics, Inc. Common Stock on the Closelook wire is a price target by Truist on 2026-08-13 (target 135 from 81). 1 action on the analyst wire since 2026-08-13: 1 target change. Analyst actions are third-party opinions recorded by the wire, not Closelook readings. The “The Street on this name” block on this page lists the moves; the full feeds are the analyst wire and the earnings wire.

What does this page show?

A live price chart with SMA overlays and drawing tools for APGE, performance metrics, index-membership context and the Closelook structure read — an investment research diary view, not investment advice.

Related in the Closelook universe

then Biotechnology. Scored names rank on their Closelook score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.